AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate placebo
Description: Mometasone furoate placebo matching nasal spray, once daily
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate placebo
Description: Mometasone furoate placebo matching nasal spray, once daily
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Fluticasone propionate placebo matching nasal spray, once daily
Study NCT03461614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate placebo
Description: Fluticasone propionate placebo matching nasal spray, once daily
Study NCT00952783 — intervention group
Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study NCT04414215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional working memory training
Description: Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
Study NCT04414215 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo working memory training
Description: Working memory training that does not involve emotional stimuli using an N-back training program
Study NCT02456532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: six months of nightly placebo
Study NCT02456532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem CR
Description: six months of nightly zolpidem
Study NCT02456532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Study NCT04314739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Participants will consume one of the treatment types daily for a period of four weeks.
Study NCT04314739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume one of the treatment types daily for a period of four weeks.
Study NCT03882320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Description: Patient Controlled Analgesia (PCA)
Study NCT03882320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Description: Patient Controlled Analgesia (PCA)
Study NCT00376220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
Study NCT00376220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
Study NCT03713268 — intervention group
Intervention type: DEVICE
Intervention: Microscope integrated optical coherence tomography
Description: This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
Study NCT04068142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Supporter Safety Planning
Description: The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
Study NCT02563522 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Engensis (VM202)
Description: gene therapy
Study NCT03461614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
Study NCT02426021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202
Study NCT02563522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care plus placebo
Study NCT03365323 — intervention group
Intervention type: OTHER
Intervention: Periprosthetic Joint Infection
Description: Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
Study NCT03365323 — intervention group
Intervention type: OTHER
Intervention: Non-Periprosthetic Joint Infection
Description: PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
Study NCT00681720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Single dose of oral solution or capsule. 3 times per subject.
Study NCT00681720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioligand (11C) flumazenil
Description: Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
Study NCT02745977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dairy Free Diet
Description: Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
Study NCT00668070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9831
Description: Oral
Study NCT00668070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01429584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene nerve block with 0.25% bupivacaine
Description: interscalene nerve block performed with 20 ml of 0.25% bupivacaine
Study NCT01429584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block with 0.125% bupivacaine
Description: interscalene block with 20 ml of 0.125% bupivacaine
Study NCT00747643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Participants in this group received varenicline according to the schedule in the Arm Description.
Study NCT00747643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
Study NCT03588351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan nanoparticles gel
Description: intracanal medicament
Study NCT03588351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan gel
Description: intracanal medicament
Study NCT03588351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: intracanal medicament
Study NCT03215550 — intervention group
Intervention type: PROCEDURE
Intervention: CEA
Description: Carotid Endarterectomy
Study NCT03215550 — intervention group
Intervention type: RADIATION
Intervention: 18F PET-MRI
Description: 18F-fluoride Hybrid PET-MRI
Study NCT03215550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Microembolic Signals detection
Study NCT02847455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ilaprazole
Description: One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
Study NCT02847455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT02847455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rabeprazole
Description: one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00737256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 15-30 mg
Study NCT00737256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: 8-16 mg
Study NCT01357096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated health care team
Description: CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
Study NCT01357096 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Traditional group
Description: CAD education fryers
Study NCT00063141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
Study NCT00063141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Study NCT00063141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Study NCT01187966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study NCT01187966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03897907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychologically Informed Education Video
Description: The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)
Study NCT03897907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anatomy Education Video
Description: Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
Study NCT00641550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Walking 3 times a week during 1 hours (moderate activity)
Study NCT04155255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyBFF@school
Study NCT00319150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: Decrease dosage by 12.5% q 2 weeks according to an algorithm.
Study NCT03722342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001 and pembrolizumab combination
Description: * Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)
Study NCT04501068 — intervention group
Intervention type: DEVICE
Intervention: Ambu® AuraGainTM
Description: Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
Study NCT03416270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
Study NCT03416270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks
Study NCT01262768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Measurement Aids (PSMAs)
Description: Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
Study NCT01469182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641
Description: Rapidly dissolving tablet sublingually once daily
Study NCT01469182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SCH 39641
Description: Rapidly dissolving tablet sublingually once daily
Study NCT03562130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Daily sub cutaneous injection 0,05 mg/kg/day
Study NCT02114164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal System
Description: To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
Study NCT02114164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endopath
Description: This group receives the Standard Endopath Trocar for intraoperative insufflation.
Study NCT00096785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
Study NCT00096785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir
Description: Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
Study NCT01867060 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Automated Cardiac Event Recorder
Description: Automated Cardiac Event Recorder to be worn continuously for one week.
Study NCT01867060 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Personal Heart Rhythm Monitor
Description: Personal Heart Rhythm Monitor to be used twice-daily for three months.
Study NCT01719315 — intervention group
Intervention type: OTHER
Intervention: Acoustical slow wave induction
Description: Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
Study NCT03982836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Dietary Fibers
Description: All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
Study NCT03982836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Dietary Fibers
Description: All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
Study NCT03119961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOCLOUD®
Description: BBB opening by ultrasound
Study NCT00257725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-MPH
Description: Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
Study NCT02573870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol + Fluticasone Furoate
Description: Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
Study NCT02573870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
Study NCT02573870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
Study NCT02573870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
Study NCT02792270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction Diet
Description: Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein.